Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01057277 · ClinicalTrials.gov registry record · Phase 1
RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer
A Phase 1 study, sponsored by howard safran.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01057277: Clinical Trial Phase 1 study, sponsored by howard safran.
NCT01057277 is a Phase 1 study that was terminated before completion, run by howard safran. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01057277, a Phase 1 study, was terminated before completion, sponsored by howard safran.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if RAD001, to a maximum dose of 10 mg/day, can be safely administered with cisplatin, and concurrent radiotherapy, for patients with locally advanced, inoperable, squamous cell carcinoma of the head and neck.
Interventions
- DRUG RAD001(Afinitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Why NCT01057277 stopped before completion
NCT01057277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which RAD001(Afinitor) is the first listed.
NCT01057277 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01057277 about?
NCT01057277 is a clinical study titled "RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer". The purpose of this study is to determine if RAD001, to a maximum dose of 10 mg/day, can be safely administered with cisplatin, and concurrent radiotherapy, for patients with locally advanced, inoperable, squamous cell carcinoma of the head and neck.
What is the current status of trial NCT01057277?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2009-12. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01057277?
The interventions under investigation include: RAD001(Afinitor) (DRUG).
Who is sponsoring clinical trial NCT01057277?
This trial is sponsored by howard safran, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01057277's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia